UBS maintains Buy rating on Colgate-Palmolive, PT down to $92 from $99.

UBS maintains Buy rating on Colgate-Palmolive, PT down to $92 from $99.

September 12, 2025

UBS Group AG has maintained its Buy rating on Colgate-Palmolive Company (NYSE:CL), but has revised its price target downward from $99 to $92. This adjustment comes amidst a series of analyst downgrades and upgrades on the stock, reflecting varying market sentiments and recent financial performance.

In the latest earnings report, Colgate-Palmolive delivered $0.92 earnings per share, surpassing the estimated $0.89, and reported revenue of $5.11 billion, beating analysts' expectations of $5.03 billion. The company also announced a quarterly dividend of $0.52 per share, yielding 2.7%, with the payment date set for November 14th.

Several other analysts have also made notable changes to their price targets and ratings on Colgate-Palmolive. Barclays lowered its target from $87 to $82, while JPMorgan Chase & Co. decreased its target from $99 to $95. Wells Fargo & Company lowered its target from $83 to $80, and Citigroup adjusted its target from $108 to $105. Despite these changes, UBS remains optimistic about the company's prospects, citing strong fundamentals and a solid dividend history.

Institutional investors and hedge funds continue to show significant interest in Colgate-Palmolive, with several funds increasing their stakes in the company during the second quarter. Vicus Capital, for instance, reduced its holdings by 16.2%, but still owns 55,192 shares valued at $5,017,000. Meanwhile, Boston Common Asset Management LLC increased its holdings by 2.2%, owning 302,551 shares valued at $27,502,000 as of its most recent filing.

Colgate-Palmolive's stock has shown resilience, trading between a one-year low of $78.76 and a high of $102.61. The company's debt-to-equity ratio stands at 6.79, and its market capitalization is $63.81 billion. Analysts predict that Colgate-Palmolive will post 3.75 earnings per share for the current fiscal year.

Despite the downward adjustment in price target, UBS's continued Buy rating suggests that the investment community remains bullish on Colgate-Palmolive's long-term prospects. The company's strong financial performance and robust dividend history continue to attract investors, making it a key player in the consumer goods sector.